Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1306 related articles for article (PubMed ID: 34646270)

  • 1. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.
    Cai Z; Zhan P; Song Y; Liu H; Lv T
    Transl Lung Cancer Res; 2022 Aug; 11(8):1555-1566. PubMed ID: 36090645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
    Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
    Dolladille C; Ederhy S; Sassier M; Cautela J; Thuny F; Cohen AA; Fedrizzi S; Chrétien B; Da-Silva A; Plane AF; Legallois D; Milliez PU; Lelong-Boulouard V; Alexandre J
    JAMA Oncol; 2020 Jun; 6(6):865-871. PubMed ID: 32297899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V; Patwari A; Harb AJ
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
    BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
    Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
    Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study.
    Yang J; Zeng R; Zhou J; Luo L; Lyu M; Liu F; Sun X; Zhou L; Wang X; Bao Z; Chen W; Dumoulin DW; Gao B; Xiang Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1038-1050. PubMed ID: 35832441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events.
    Guo M; VanderWalde AM; Yu X; Vidal GA; Tian GG
    Clin Lung Cancer; 2022 Dec; 23(8):686-693. PubMed ID: 36050243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
    Torasawa M; Yoshida T; Takeyasu Y; Shimoda Y; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
    Cancer Med; 2023 Jun; 12(11):12388-12401. PubMed ID: 37062059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis.
    Xu S; Shukuya T; Tamura J; Shimamura S; Kurokawa K; Miura K; Miyawaki T; Hayakawa D; Asao T; Yamamoto K; Takahashi K
    JTO Clin Res Rep; 2022 Apr; 3(4):100309. PubMed ID: 35434666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
    Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
    Front Oncol; 2022; 12():934093. PubMed ID: 35912183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
    Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
    Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis.
    Guzman-Prado Y; Ben Shimol J; Samson O
    Cancer Immunol Immunother; 2021 Jan; 70(1):89-100. PubMed ID: 32648164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
    Song P; Zhang D; Cui X; Zhang L
    Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.